These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 20952469)

  • 1. Adalimumab improves sleep and sleep quality in patients with active ankylosing spondylitis.
    Rudwaleit M; Gooch K; Michel B; Herold M; Thörner A; Wong R; Kron M; Chen N; Kupper H
    J Rheumatol; 2011 Jan; 38(1):79-86. PubMed ID: 20952469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).
    Revicki DA; Luo MP; Wordsworth P; Wong RL; Chen N; Davis JC;
    J Rheumatol; 2008 Jul; 35(7):1346-53. PubMed ID: 18484692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.
    Davis JC; Revicki D; van der Heijde DM; Rentz AM; Wong RL; Kupper H; Luo MP
    Arthritis Rheum; 2007 Aug; 57(6):1050-7. PubMed ID: 17665483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis.
    Maksymowych WP; Gooch KL; Wong RL; Kupper H; van der Heijde D
    J Rheumatol; 2010 Feb; 37(2):385-92. PubMed ID: 19955052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.
    Strober BE; Sobell JM; Duffin KC; Bao Y; Guérin A; Yang H; Goldblum O; Okun MM; Mulani PM
    Br J Dermatol; 2012 Dec; 167(6):1374-81. PubMed ID: 22897348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis.
    Hu Z; Xu M; Li Q; Lin Z; Liao Z; Cao S; Wei Q; Zhang YL; Li T; Jin O; Huang J; Pan Y; Wu Y; Deng X; Gu J
    Int J Rheum Dis; 2012 Aug; 15(4):358-65. PubMed ID: 22898215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Lambert RG; Salonen D; Rahman P; Inman RD; Wong RL; Einstein SG; Thomson GT; Beaulieu A; Choquette D; Maksymowych WP
    Arthritis Rheum; 2007 Dec; 56(12):4005-14. PubMed ID: 18050198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis.
    Maksymowych WP; Rahman P; Shojania K; Olszynski WP; Thomson GT; Ballal S; Wong RL; Inman RD;
    J Rheumatol; 2008 Oct; 35(10):2030-7. PubMed ID: 18785308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial.
    Huang F; Gu J; Zhu P; Bao C; Xu J; Xu H; Wu H; Wang G; Shi Q; Andhivarothai N; Anderson J; Pangan AL
    Ann Rheum Dis; 2014 Mar; 73(3):587-94. PubMed ID: 23475983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    van der Heijde D; Kivitz A; Schiff MH; Sieper J; Dijkmans BA; Braun J; Dougados M; Reveille JD; Wong RL; Kupper H; Davis JC;
    Arthritis Rheum; 2006 Jul; 54(7):2136-46. PubMed ID: 16802350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis.
    Paramarta JE; De Rycke L; Heijda TF; Ambarus CA; Vos K; Dinant HJ; Tak PP; Baeten DL
    Ann Rheum Dis; 2013 Nov; 72(11):1793-9. PubMed ID: 23139265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: results from a randomized, placebo-controlled trial.
    Deodhar A; Braun J; Inman RD; Mack M; Parasuraman S; Buchanan J; Hsu B; Gathany T; van der Heijde D
    Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1266-71. PubMed ID: 20506403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.
    Rudwaleit M; Claudepierre P; Wordsworth P; Cortina EL; Sieper J; Kron M; Carcereri-De-Prati R; Kupper H; Kary S
    J Rheumatol; 2009 Apr; 36(4):801-8. PubMed ID: 19273449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.
    van der Heijde D; Breban M; Halter D; DiVittorio G; Bratt J; Cantini F; Kary S; Pangan AL; Kupper H; Rathmann SS; Sieper J; Mease PJ
    Rheumatology (Oxford); 2015 Jul; 54(7):1210-9. PubMed ID: 25541333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis.
    Braun J; Rudwaleit M; Kary S; Kron M; Wong RL; Kupper H
    Rheumatology (Oxford); 2010 Aug; 49(8):1578-89. PubMed ID: 20448079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement.
    Rejón E; Giménez MD; Mayordomo L; Rodríguez S; González MP; Marenco JL
    Scand J Rheumatol; 2004; 33(5):323-6. PubMed ID: 15513681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
    Braun J; McHugh N; Singh A; Wajdula JS; Sato R
    Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
    Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
    Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
    Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.